Maternal medication use and neuroblastoma in offspring

American Journal of Epidemiology

Volumn 159, Issue 8, 2004, Pages 721-731

  Cook, Michael N ^a   Olshan, Andrew F ^a,e   Guess, Harry A ^a   Savitz, David A ^a   Poole, Charles ^a   Blatt, Julie ^b   Bondy, Melissa L ^c   Pollock, Brad H ^d  

^a IL   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d Mays Cancer Center at UT Health San Antonio   (United States)

^e CHILDREN S ONCOLOGY GROUP   (United States)

Author keywords

Case control studies; Child; Codeine; Neuroblastoma; Pregnancy; Risk factors

Indexed keywords

ACETYLSALICYLIC ACID; ADRENERGIC RECEPTOR STIMULATING AGENT; AMOXICILLIN; AMPICILLIN; ANALGESIC AGENT; ANTICONVULSIVE AGENT; ANTIHISTAMINIC AGENT; ANTIINFECTIVE AGENT; ANTITUSSIVE AGENT; BROMPHENIRAMINE; CEFALEXIN; CHLORPHENIRAMINE; CODEINE; DIPHENHYDRAMINE; DIURETIC AGENT; DOXYLAMINE; ERYTHROMYCIN; ESTROGEN; EXPECTORANT AGENT; GESTAGEN; HORMONE; NITROFURANTOIN; NITROSO DERIVATIVE; OPIATE AGONIST; PENICILLIN G; PROMETHAZINE; SEDATIVE AGENT; SULFAMETHOXAZOLE; TRIMETHOPRIM; UNINDEXED DRUG; NARCOTIC AGENT;

DRUG USER; MATERNAL HEALTH; PREGNANCY;

ADOLESCENT; ADULT; ARTICLE; CANADA; CASE CONTROL STUDY; CHILD; CONTROLLED STUDY; DATA ANALYSIS; DEMOGRAPHY; DISEASE ASSOCIATION; EVALUATION; FEMALE; HOSPITAL CARE; HUMAN; INFANT; INTERVIEW; LACTATION; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; NEUROBLASTOMA; PREGNANCY COMPLICATION; PRENATAL DRUG EXPOSURE; SAMPLING; SOCIOECONOMICS; TELEPHONE; UNITED STATES; CHEMICALLY INDUCED DISORDER; NEWBORN; PREGNANCY; PRENATAL EXPOSURE; PRESCHOOL CHILD; RETROSPECTIVE STUDY; RISK FACTOR; STATISTICAL MODEL;

ADULT; CANADA; CASE-CONTROL STUDIES; CHILD, PRESCHOOL; CODEINE; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; INTERVIEWS; LOGISTIC MODELS; NARCOTICS; NEUROBLASTOMA; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS; RETROSPECTIVE STUDIES; RISK FACTORS; UNITED STATES;

EID: 2342523983     PISSN: 00029262     EISSN: None     Source Type: Journal    
DOI: 10.1093/aje/kwh108     Document Type: Article

References (65)

1. Brodeur GM, Castleberry RP. Neuroblastoma. In: Pizzo PA, Poplack DG, eds. Principles and practice of pediatric oncology. 3rd ed. Philadelphia, PA: Lippincott-Raven Publishers, 1997: 761-97.
2. Kenney LB, Miller BA, Ries LA, et al. Increased incidence of cancer in infants in the U.S.: 1980-1990. Cancer 1998;82: 1396-400.
3. Gurney JG, Davis S, Severson RK, et al. Trends in cancer incidence among children in the US. Cancer 1996;78:532-41.
4. Goodman MT, Gurney JG, Smith MA, et al. Sympathetic nervous system tumors. In: Ries LA, Smith MA, Gurney JG, et al, eds. Cancer incidence and survival among children and adolescents: United States SEER Program 1975-1995. Bethesda, MD: National Cancer Institute, 1999:65-72. (DHHS publication no. 99-4649).
5. Brodeur GM, Ambros PF. Genetic and biological markers of prognosis in neuroblastoma. In: Brodeur GM, Sawada T, Tsuchida Y, et al, eds. Neuroblastoma. Amsterdam, the Netherlands: Elsevier Science, 2000:355-69.
6. Lastowska M, Cullinane C, Variend S, et al. Comprehensive genetic and histopathologic study reveals three types of neuroblastoma tumors. J Clin Oncol 2001;19:3080-90.
7. Ambros PF, Brodeur GM. Concept of tumorigenesis and regression. In: Brodeur GM, Sawada T, Tsuchida Y, et al, eds. Neuroblastoma. Amsterdam, the Netherlands: Elsevier Science, 2000:21-32.
8. Olshan AF, Bunin GR. Epidemiology of neuroblastoma. In: Brodeur GM, Sawada T, Tsuchida Y, et al, eds. Neuroblastoma. Amsterdam, the Netherlands: Elsevier Science, 2000:33-9.
9. Schuz J, Kaletsch U, Meinert R, et al. Risk factors for neuroblastoma at different stages of disease: results from a population-based case-control study. J Clin Epidemiol 2001;54:702-9.
10. Kramer S, Ward E, Meadows AT, et al. Medical and drug risk factors associated with neuroblastoma: a case-control study. J Natl Cancer Inst 1987;78:797-804.
11. Michalek AM, Buck GM, Nasca PC, et al. Gravid health status, medication use, and risk of neuroblastoma. Am J Epidemiol 1996;143:996-1001.
12. Mandel M, Toren A, Rechavi G, et al. Hormonal treatment in pregnancy: a possible risk factor for neuroblastoma. Med Pediatr Oncol 1994;23:133-5.
13. Thapa PB, Whitlock JA, Brockman Worrell KG, et al. Prenatal exposure to metronidazole and risk of childhood cancer: a retrospective cohort study of children younger than 5 years. Cancer 1998;83:1461-8.
14. Schwartzbaum JA. Influence of the mother's prenatal drug consumption on risk of neuroblastoma in the child. Am J Epidemiol 1992;135:1358-67.
15. Walters CL, Gillatt PH, Palmer RC, et al. Nitrosation of drugs under in-vivo conditions. In: Bartsch H, O'Neill IK, Schulte-Hermann R, eds. Relevance of N-nitroso compounds to human cancer: exposures and mechanisms. (IARC Scientific Publication no. 84). Lyon, France: International Agency for Research on Cancer, 1987:351-4.
16. Olshan AF, Smith J, Cook MN, et al. Hormone and fertility drug use and the risk of neuroblastoma: a report from the Children's Cancer Group and the Pediatric Oncology Group. Am J Epidemiol 1999;150:930-8.
17. Olshan AF, Smith JC, Bondy ML, et al. Maternal vitamin use and reduced risk of neuroblastoma. Epidemiology 2002;13: 575-80.
18. Robison LL, Daigle A. Control selection using random digit dialing for cases of childhood cancer. Am J Epidemiol 1984; 120:164-6.
19. Waksberg J. Sampling methods for random digit dialing. J Am Stat Assoc 1978;73:40-6.
20. Kaufman DW, Rosenberg L, Mitchell AA. Signal generation and clarification: use of case-control data. Pharmacoepidemiol Drug Res 2001;10:197-203.
21. Greenland S, Schwartzbaum JA, Finkle WD. Problems due to small samples and sparse data in conditional logistic regression analysis. Am J Epidemiol 2000;151:531-9.
22. Brodeur GM, Seeger RC, Schwab M, et al. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science 1984;224:1121-4.
23. Shapiro DN, Valentine MB, Rowe ST, et al. Detection of N-myc gene amplification by fluorescence in situ hybridization: diagnostic utility for neuroblastoma. Am J Pathol 1993;142: 1339-46.
24. Piper JM, Mitchel EF. Prenatal exposure to prescribed drugs in Tennessee Medicaid, 1983-1988. Paediatr Perinatal Epidemiol 1991;5:402-9.
25. Piper JM, Baum C, Kennedy DL. Prescription drug use before and during pregnancy in a Medicaid population. Am J Obstet Gynecol 1987;157:148-56.
26. Michaelis J, Haaf HG, Zollner J, et al. Case control study of neuroblastoma in West-Germany after the Chernobyl accident. Klin Padiatr 1996;208:172-8.
27. Al-Shammri S, Guberman A, Hsu E. Neuroblastoma and fetal exposure to phenytoin in a child without dysmorphic features. Can J Neurol Sci 1992;19:243-5.
28. Ivankovic S. Experimental prenatal carcinogenesis. In: Tomatis L, Mohr U, eds. Transplacental carcinogenesis. (IARC Scientific Publication no. 4). Lyon, France: International Agency for Research on Cancer, 1973:92-9.
29. Rice JM, Ward JM. Age dependence of susceptibility to carcinogenesis in the nervous system. Ann N Y Acad Sci 1982; 381:274-89.
30. Oda H, Zhang S, Tsurutani N, et al. Loss of p53 is an early event in induction of brain tumors in mice by transplacental carcinogen exposure. Cancer Res 1997;57:646-50.
31. Blot WJ, Henderson BE, Boice JD Jr. Childhood cancer in relation to cured meat intake: review of the epidemiological evidence. Nutr Cancer 1999;34:111-18.
32. Mertens AC, Robison LL. Evaluation of parental participation in a case-control study of infant leukaemia. Paediatr Perinat Epidemiol 1997;11:240-6.
33. West SL, Strom BL, Poole C. Validity of pharmacoepidemiology drug and diagnosis data. In: Strom BL, ed. Pharmacoepidemiology. 3rd ed. New York, NY: John Wiley and Sons, Inc, 2000:661-706.
34. Jick H, Holmes LB, Hunter JR, et al. First-trimester drug use and congenital disorders. JAMA 1981;246:343-6.
35. Klemetti A, Saxen L. Prospective versus retrospective approach in the search for environmental causes of malformations. Am J Public Health 1967;57:2071-5.
36. Mackenzie SG, Lippmann A. An investigation of report bias in a case-control study of pregnancy outcome. Am J Epidemiol 1989;129:65-75.
37. Feldman Y, Koren G, Mattice D, et al. Determinants of recall and recall bias in studying drug and chemical exposure during pregnancy. Teratology 1989;40:37-45.
38. de Jong PC, Berns MP, van Duynhoven YT, et al. Recall of medication during pregnancy: validity and accuracy of an adjusted questionnaire. Pharmacoepidemiol Drug Saf 1995;4: 23-30.
39. Stone AA, Turkkan JS, Bachrach CA, et al, eds. The science of self-report: implications for research and practice. Mahwah, NJ: Lawrence Erlbaum, 2000.
40. Schwarz N, Sudman S, eds. Autobiographical memory and the validity of retrospective reports. New York, NY: Springer Verlag, 1994.
41. Bryant HE, Visser N, Love EJ. Records, recall loss, and recall bias in pregnancy: a comparison of interview and medical records data of pregnant and postnatal women. Am J Public Health 1989;79:78-80.
42. Mitchell AA, Cottler LB, Shapiro S. Effect of questionnaire design on recall of drug exposure in pregnancy. Am J Epidemiol 1986;123:670-6.
43. Cottler LB, Robins LN. The effect of questionnaire design on reported prevalence of psychoactive medications. In: Harris LS, ed. Problems of drug dependence. Washington, DC: National Institute on Drug Abuse, 1994:231-7. (DHHS publication no. 55-1393).
44. Kimmel SE, Lewis JD, Jaskowiak J, et al. Enhancement of medication recall using medication pictures and lists in telephone interviews. Pharmacoepidemiol Drug Saf 2003;12:1-8.
45. Paulose-Ram R, Hirsch R, Dillon C, et al. Prescription and non-prescription analgesic use among the US adult population: results from the Third National Health and Nutrition Examination Survey (NHANES III). Pharmacoepidemiol Drug Saf 2003;12:315-26.
46. Rubin JD, Ferencz C, Loffredo C, et al. Use of prescription and non-prescription drugs during pregnancy. J Clin Epidemiol 1993;6:581-9.
47. Raphael K. Recall bias: a proposal for assessment and control. Int J Epidemiol 1987;16:167-70.
48. Coughlin SS. Recall bias in epidemiologic studies. J Clin Epidemiol 1990;43:87-91.
49. McCredie J, Kricker A, Elliott J, et al. The innocent bystander: doxylamine/dicyclomine/pyridoxine and congenital limb defects. Med J Aust 1984;140:525-7.
50. Tilley BC, Barnes AB, Bergstralh E, et al. A comparison of pregnancy history recall and medical records: implications for retrospective studies. Am J Epidemiol 1985;121:269-81.
51. Werler MM, Pober BR, Nelson K, et al. Reporting accuracy among mothers of malformed and nonmalformed infants. Am J Epidemiol 1989;129:415-21.
52. Drews CD, Kraus JF, Greenland S. Recall bias in a case-control study of sudden infant death syndrome. Int J Epidemiol 1990; 19:405-11.
53. Delgado-Rodriguez M, Gomez-Olmedo M, Bueno-Cavanillas A, et al. Recall bias in a case-control study of low birth weight. J Clin Epidemiol 1995;48:1133-40.
54. Rockenbauer M, Olsen J, Czeizel AE, et al. Recall bias in a case-control surveillance system on the use of medicine during pregnancy. Epidemiology 2001;12:461-6.
55. Hamrick SE, Olshan AF, Neglia JP, et al. Association of pregnancy history and birth characteristics with neuroblastoma: a report from the Children's Cancer Group and the Pediatric Oncology Group. Paediatr Perinat Epidemiol 2001;15:328-37.
56. De Roos AJ, Poole C, Teschke K, et al. An application of hierarchical regression in the investigation of multiple paternal occupational exposures and neuroblastoma in offspring. Am J Ind Med 2001;39:477-86.
57. Steenland K, Bray I, Greenland S, et al. Empirical Bayes adjustments for multiple results in hypothesis-generating or surveillance studies. Cancer Epidemiol Biomarkers Prev 2000;9:895-903.
58. 1 mice (feed studies). (National Toxicology Program technical report no. 455). Bethesda, MD: National Institutes of Health, 1996. (NIH publication no. 96-3360).
59. Khan K, Chang J. Neonatal abstinence syndrome due to codeine. Arch Dis Child Fetal Neonatal Ed 1997;76:F59-60.
60. Meny RG, Naumburg EG, Alger LS, et al. Codeine and the breastfed neonate. J Hum Lact 1993;9:237-40.
61. Findlay JW, DeAngelis RL, Kearney MF, et al. Analgesic drugs in breast milk and plasma. Clin Pharmacol Ther 1981;22: 439-46.
62. Meijerink WJ, Molina PE, Abumrad NN. Mammalian opiate alkaloid synthesis: lessons derived from plant biochemistry. Shock 1999;3:165-73.
63. Donnerer J, Cardinale G, Coffey J, et al. Chemical characterization and regulation of endogenous morphine and codeine in the rat. J Pharmacol Exp Ther 1987;242:583-7.
64. McLaughlin PJ, Zagon IS, Skitzki J. Human neuroblastoma cell growth in tissue culture is regulated by opioid growth factor. Int J Oncol 1999;14:373-80.
65. McLaughlin PJ, Zagon IS. Modulation of human neuroblastoma transplanted into nude mice by endogenous opioid systems. Life Sci 1987;41:1465-72.